Medpace Holdings, Inc. — Q1 2023 Form 10-Q
Business context and reporting period. Medpace is a global clinical research organization providing drug and medical-device development services. This unaudited report covers the three months ended March 31, 2023, compared with Q1 2022, and the balance sheet as of March 31, 2023.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / prior date | Change |
|---|---|---|---|
| Revenue | $434.1 million | $330.9 million | +31.2% |
| Operating income | $86.2 million | $64.2 million | +34.3% |
| Operating margin | 19.9% | 19.4% | +0.5 percentage points |
| Net income | $72.9 million | $61.3 million | +18.9% |
| Net margin | 16.8% | 18.5% | −1.7 percentage points |
| Diluted EPS | $2.27 | $1.69 | +34.3% |
| Operating cash flow | $80.1 million | $46.3 million | +$33.8 million |
| Capital expenditures | $9.5 million | $9.3 million | +$0.3 million |
| Cash and cash equivalents | $46.9 million | $28.3 million at Dec. 31, 2022 | +$18.7 million |
| Revolving credit facility debt | $115.0 million | $50.0 million at Dec. 31, 2022 | +$65.0 million |
Revenue growth was primarily driven by Oncology, Metabolic, Cardiology and other therapeutic areas. Direct costs rose 30.8%, including a $46.0 million increase in reimbursed out-of-pocket expenses and higher personnel costs. SG&A increased 29.5%, mainly due to personnel costs. The effective tax rate was 15.3%, versus 6.1% in Q1 2022; the filing attributes the increase to higher pretax income and reduced tax benefits compared with the prior-year period.
Cash generated from operations was $80.1 million. Investing activities used $9.5 million, while financing activities used $52.7 million, including $120.1 million of share repurchases, partly offset by net credit-facility borrowings. The company repurchased 654,787 shares at an average $183.45 per share; $332.7 million remained authorized under its repurchase program at quarter-end. Weighted-average diluted shares declined to 32.2 million from 36.4 million.
Current liabilities were $881.9 million and total liabilities were $1.05 billion at quarter-end. Advanced billings were $466.0 million. The company reported $34.8 million available under its credit facility. The facility’s borrowing limit was amended to $150.0 million on March 31, 2023, with an expiration date of March 29, 2024; the stated interest rate was 6.0%. Total operating lease liabilities were $161.9 million.
Material changes and business indicators
- Net new business awards were $555.8 million, up from $423.0 million in Q1 2022.
- Backlog reached $2.46 billion at March 31, 2023, up 17.8% from $2.09 billion a year earlier. Medpace expected $1.32–$1.34 billion of that backlog to convert to revenue over the next 12 months.
- The company reported approximately $2.9 billion of remaining performance obligations for active projects; this figure is distinct from reported backlog.
- Q1 2023 repurchases were substantially below the $425.9 million spent in Q1 2022.
Outlook, risks, contingencies and unusual items
The filing provides no specific revenue, earnings or margin guidance. Management said expected cash needs include operating growth, capital expenditures, debt repayment, share repurchases, selective bolt-on acquisitions and other corporate needs, and expects to fund them with cash, operating cash flow and, if necessary, borrowings. It also cautioned that awards and backlog may not reliably predict future revenue because of changes in project scope, cancellations, service timing and foreign-exchange movements. Customer contracts generally permit termination, typically on 30 days’ notice.
Risk factors were reported as unchanged from the 2022 Form 10-K. The filing notes exposure to foreign-exchange movements, inflation and pricing pressures, among other forward-looking uncertainties. Legal proceedings were described as ordinary-course matters; management considered potential losses immaterial. Project-supply purchase commitments totaled $17.1 million, expiring through 2029.
Related-party matters warrant attention: executives, including the CEO, have connections to customers LIB Therapeutics and CinRx; Q1 revenue from them was $13.3 million and $2.5 million, respectively. The company also leases Cincinnati properties from entities owned by the CEO and family members. The headquarters lease was renewed for ten years through December 2032. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether backlog and award growth convert into revenue on the expected schedule, and how cancellations or scope changes affect conversion.
- Whether cost growth, particularly personnel and reimbursable expenses, remains aligned with revenue growth and supports margins.
- Cash needs and refinancing or repayment capacity, given $115.0 million of facility borrowings, the 2024 facility expiration, and ongoing repurchases.
- The sustainability of the effective tax rate and diluted EPS growth, including the effects of share-based compensation tax benefits and the reduced share count.
- Related-party customer and lease arrangements, including their scale, terms and governance oversight.